Cyteir Therapeutics (CYT) 10-K/A 2 May 23 2022 FY Annual report (amended) Financial data

Document Entity Information

Document Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 20, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	Cyteir Therapeutics, Inc.
Entity Central Index Key	0001662244
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		35,646,971
Entity Public Float			$ 69,456,355
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Security12b Title	Common Stock, par value $0.001 per share
Trading Symbol	CYT
Security Exchange Name	NASDAQ
Entity File Number	001-40499
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	45-5429901
Entity Address Address Line One	99 Hayden Ave., Building B
Entity Address, Address Line Two	Suite 450
Entity Address City Or Town	Lexington
Entity Address State Or Province	MA
Entity Address Postal Zip Code	02421
City Area Code	857
Local Phone Number	285-4140
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE A definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders was filed with the Securities and Exchange Commission on April 27, 2023. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.
Amendment Description	On March 23, 2023, Cyteir Therapeutics, Inc. (the “Company”) filed its Annual Report on Form 10-K (the “Original Form 10-K”). The purpose of this Amendment No. 1 to the Original Form 10-K (the "Amendment") is solely to correct the inadvertent omission of paragraph 4(b) from Exhibit 31.1, Certification of the Chief Executive Officer, and Exhibit 31.2, Certification of the Chief Financial Officer (together, the “Certifications”), each as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). New Certifications with the appropriate corrections are filed as Exhibits 31.1 and 31.2 attached hereto, respectively. Because no financial statements are included with this Amendment, paragraph 3 of the certifications in Exhibits 31.1 and 31.2 has been omitted. No other items of the Original Form 10-K are being amended and this Amendment does not reflect any events occurring after the filing of the Original Form 10-K and the Original Form 10-K continues to speak as of the date of the Original Form 10-K. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K and the Company’s filings made with the SEC subsequent to the Original Form 10-K.
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Boston, MA